RecruitingPhase 1NCT03911388
Oncology
Gliosarcoma
16
studies recruiting now
as of 7 Sept 2026
504
studies registered in total
as of 7 Sept 2026
2
countries with a recruiting site
as of 7 Sept 2026
1 May 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1NCT04991870
Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
RecruitingPhase 1NCT05857969
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
RecruitingNCT06954636
Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study
RecruitingPhase 2NCT05864534
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 16 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Gliosarcoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Gliosarcoma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (NFKBIA, MGMT, EGFR, FGFR1, FGFR3, TP53).
Treatments being studied
33 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Temozolomide (Temodal)
Phase 3Lomustine (Ccnu)
Phase 3Bevacizumab (Abevmy)
Phase 3Rindopepimut
Phase 2Pazopanib Hydrochloride (Votrient)
Phase 2Ar-67
Phase 2Tipifarnib
Phase 2Gossypol Acetic Acid
+ 25 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).